Biocon Biologics and Yoshindo Expand Access to Ustekinumab Biosimilar in Japan

In a significant stride for biotechnology and healthcare innovation, Biocon Biologics Ltd (BBL), a global leader in pharmaceuticals, has partnered with Yoshindo Inc. to bring a biosimilar version of Ustekinumab to the Japanese market. Announced on May 21, 2025, this collaboration marks a pivotal moment for patients seeking advanced psoriasis treatment and relief from psoriatic arthritis (PsA).

Biocon Biologics, listed on the BSE (code: 532523, NSE: BIOCON), revealed that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Subcutaneous Injection (YD), a biosimilar to the reference product Stelara® (ustekinumab). Developed and manufactured by Biocon Biologics, this biosimilar targets psoriasis vulgaris and psoriatic arthritis, chronic conditions affecting millions worldwide. The launch follows regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in December 2024, a testament to Biocon’s commitment to quality in the biopharmaceutical sector.

The partnership builds on a settlement and licensing agreement signed in April 2024 with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen). This agreement allowed Yoshindo Inc. to commercialize Ustekinumab BS in Japan, expanding access to affordable and effective chronic disease management solutions for patients.

Ustekinumab, a monoclonal antibody, has already made a global impact. Biocon Biologics launched the biosimilar in the United States and Europe in February 2025, offering hope to patients managing these debilitating conditions. The introduction of this biosimilar in Japan is expected to reduce treatment costs, making advanced care more accessible in a market known for its high standards in healthcare innovation.

This development underscores Biocon Biologics’ leadership in the global biosimilar market, a sector projected to grow significantly as demand for affordable biologics rises. For patients in Japan, this launch represents a new era of psoriasis treatment options, combining cutting-edge biotechnology with affordability.

About Biocon Biologics Ltd

Biocon Biologics Ltd (BBL) is a fully integrated global biosimilars company and a subsidiary of Biocon Ltd. Headquartered in Bengaluru, India, the company focuses on developing, manufacturing, and commercializing high-quality biosimilars to address unmet medical needs worldwide.

About Yoshindo Inc.

Yoshindo Inc. is a leading pharmaceutical company in Japan, dedicated to delivering innovative and accessible healthcare solutions to improve patient outcomes.

For more information on biosimilars and their impact on chronic disease management, visit Biocon Biologics’ official website.